BST Stock Overview
Develops and markets biotechnological assets for application in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industry sectors in Spain and internationally. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Biotechnology Assets, S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.33 |
52 Week High | €0.46 |
52 Week Low | €0.24 |
Beta | 1.41 |
11 Month Change | 7.74% |
3 Month Change | 7.21% |
1 Year Change | -22.14% |
33 Year Change | -43.81% |
5 Year Change | -83.97% |
Change since IPO | -86.14% |
Recent News & Updates
Shareholder Returns
BST | ES Biotechs | ES Market | |
---|---|---|---|
7D | -9.2% | -3.9% | 1.5% |
1Y | -22.1% | -9.0% | 15.4% |
Return vs Industry: BST underperformed the Spanish Biotechs industry which returned -9% over the past year.
Return vs Market: BST underperformed the Spanish Market which returned 15.4% over the past year.
Price Volatility
BST volatility | |
---|---|
BST Average Weekly Movement | 11.5% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 3.0% |
10% most volatile stocks in ES Market | 5.6% |
10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: BST's share price has been volatile over the past 3 months compared to the Spanish market.
Volatility Over Time: BST's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1954 | 38 | Jaime Feced Rubio | www.biatgroup.com |
Biotechnology Assets, S.A. develops and markets biotechnological assets for application in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industry sectors in Spain and internationally. The company was founded in 1954 and is based in Cádiz, Spain.
Biotechnology Assets, S.A. Fundamentals Summary
BST fundamental statistics | |
---|---|
Market cap | €19.81m |
Earnings (TTM) | -€3.05m |
Revenue (TTM) | €3.37m |
6.2x
P/S Ratio-6.9x
P/E RatioIs BST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BST income statement (TTM) | |
---|---|
Revenue | €3.37m |
Cost of Revenue | €468.90k |
Gross Profit | €2.90m |
Other Expenses | €5.96m |
Earnings | -€3.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.047 |
Gross Margin | 86.10% |
Net Profit Margin | -90.49% |
Debt/Equity Ratio | 33.8% |
How did BST perform over the long term?
See historical performance and comparison